-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

637.O2.6 637. Myelodysplastic Syndromes – Clinical and Epidemiological II

Symposia: Myelodysplastic Syndromes – Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, MDS, clinical trials, adult, Clinical Practice (Health Services and Quality), Non-Biological therapies, Translational Research, Clinical Research, health outcomes research, Chronic Myeloid Malignancies, CMML, Diseases, Therapies, real-world evidence, registries, Biological Processes, Myeloid Malignancies, Study Population, Human
Sunday, December 11, 2022: 4:30 PM-6:00 PM
R06-R09 (Ernest N. Morial Convention Center)
Moderators:
Wanxing Chai-Ho, MD, David Geffen School of Medicine at UCLA and Mrinal M. M. Patnaik, MD, Mayo Clinic
Disclosures:
Chai-Ho: Gilead: Research Funding; Abbvie: Research Funding; Agios: Research Funding; Equillium: Research Funding; Kadmon: Research Funding; Syndax: Research Funding; Shattuck Lab: Research Funding; SUN pharma: Research Funding; Syros: Research Funding; Servier: Honoraria. Patnaik: Kura Oncology, Stem Line Pharmaceuticals: Research Funding.
Updates in management of MDS/MPN overlap and lower risk MDS
4:30 PM

Eric Padron, MD1, Sara M Tinsley-Vance, PhD, ANP2, Amy E. DeZern, MD3, Hetty E. Carraway, MD, MBA4, Marlise R. Luskin, MD5, Gail J. Roboz, MD6, Onyee Chan, MD2, Meagan Horton2*, Aaron T. Gerds, MD, MS7, David A. Sallman, MD1, Andrew Kuykendall, MD8, David Steensma, MD9*, Maria E Balasis2*, Jeffrey E. Lancet, MD2, Mikkael A. Sekeres, MD10 and Rami S. Komrokji2

1Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL
2Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
3Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
4Department of Hematology and Medical Oncology, Taussig Cancer institute, Leukemia Program, Cleveland Clinic, Cleveland, OH
5Dana-Farber Cancer Institute, Boston, MA
6Division of Hematology and Oncology, Weill Cornell Medicine and The New York-Presbyterian Hospital, New York, NY
7Department of Hematology and Medical Oncology,, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
8Department of Malignant Hematology, H. Lee Mofitt Cancer Center, Tampa, FL
9Novartis Institutes for BioMedical Research, Cambridge, MA
10University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL

4:45 PM

Yu-Hung Wang, MD1,2*, Chi-Yuan Yao, MD1,3, Chien-Chin Lin, MD, PhD1,3*, Kristian Gurashi4*, Fabio Amaral, PhD5*, Andres Jerez6,7*, Tim C.P Somervaille, PhD FRCP FRCPath5,8, Hsin-An Hou, MD, PhD1, Wen-Chien Chou, MD, PhD1,3, Kiran Batta, PhD9*, Hwei-Fang Tien, MD, PhD1 and Daniel H Wiseman, PhD, MB, ChB, MRCP, FRCPath2,10*

1Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
2Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom
3Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan
4University of Manchester, Manchester, United Kingdom
5Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom
6Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
7Hematology and Medical Oncology Department, Hospital Morales Meseguer, IMIB, Murcia, Spain, MURCIA, Spain
8Haematology Department, The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom
9Division of Cancer Sciences, The University of Manchester, Manchester, ENG, United Kingdom
10Haematology, The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom

5:00 PM

Uwe Platzbecker, MD1, Rami S. Komrokji, MD2, Pierre Fenaux3, Mikkael A. Sekeres, MD4, Michael Robert Savona5*, Yazan F. Madanat, MD6, Koen Van Eygen, MD7*, Azra Raza, MD8,9, Ulrich Germing10*, Laurie Sherman, BSN11, Tymara Berry, MD12*, Souria Dougherty, BS, MBA12*, Sheetal Shah12*, Libo Sun, PhD12*, Ying Wan, PhD11*, Fei Huang, PhD12*, Annat Ikin12*, Faye Feller, MD11, Amer M. Zeidan, MD13 and Valeria Santini, MD14

1University Hospital Leipzig, Leipzig, Germany
2Moffitt Cancer Center, Tampa, FL
3Hôpital St Louis/Paris 7 University, PARIS, FRA
4Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
5Vanderbilt University Medical Center, Nashville, TN
6Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX
7UT Southwestern Medical Center, Dallas
8Columbia Presbyterian, New York, NY
9Myelodysplastic Syndrome Center, Columbia University Medical Center, New York, NY
10University Hospital of Düsseldorf, Düsseldorf, Germany
11Geron Corporation, Parsippany, NJ
12Geron Corporation, Parsippany
13Yale University School of Medicine, New Haven, CT
14DMSC, MDS Unit, AOU Careggi, University of Florence, Firenze, Italy

5:15 PM

Félix López Cadenas, MD1*, Eva Lumbreras2*, Teresa González, PhD2*, Blanca Xicoy, MD3*, Joaquín Sánchez-García, MD, PhD4*, Rosa Coll, MD5*, Bohrane Slama6*, José Ángel Hernández-Rivas7*, Sylvain Thepot8*, Teresa Bernal, MD, PhD9*, Agnès Guerci-Bresler, MD, PhD10*, Guillermo Sanz, MD, PhD11,12, Joan Bargay, MD, PhD13*, Maria Luz Amigo, MD14*, Raquel De Paz Arias, PhD15*, Claude Preudhomme, PharmD, PhD16,17, Aristoteles Giagounidis, MD18, Uwe Platzbecker, MD19*, Stefan Wickenhauser, MD20*, Katharina S. Goetze21, Ali Arar22*, Jesús María Hernández-Rivas, MD, PhD2,23, Sofía M Toribio Castelló2*, Pierre Fenaux24, Consuelo Del Cañizo, MD, PhD25 and Maria Diez-Campelo, MD26*

1Hematology Department, Hospital Clínico Universitario de Salamanca, Salamanca, Spain
2Unidad de Diagnóstico Molecular y Celular del Cáncer, Centro de Investigación del Cáncer-Universidad de Salamanca (IBMCC, USAL-CSIC); Genética Molecular en Oncohematología, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
3Hematology Department, Institut Català d’Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain
4Hematology Department, Hospital Reina Sofía, Córdoba, Spain
5Hematology Department. Institut Català d’Oncologia. Hospital Doctor Josep Trueta. Institut d'Investigació Biomèdica de Girona (IDIBGI), Universitat de Girona, Girona, Spain
6CH Avignon, Avignon, FRA
7Hematology Department, Hospital Universitario Infanta Leonor, Madrid, Spain
8Department of Clinical Hematology, Angers University Hospital, Angers, France
9Hospital Universitario Central de Asturias, Instituto Universitario (IUOPA), Instituto de investigación del Principado de Asturias (ISPA), Oviedo, Spain
10Service d'Hématologie, Centre Hospitalier Universtaire Brabois, Vandoeuvre-lès-Nancy, France
11Istituto de Investigación Sanitaria La Fe, Valencia, Spain
12Hematology Deparment, Health Research Institute La Fe, Valencia, Spain
13Department of Hematology, Son Llatzer University Hospital/ IdISBa, Palma de Mallorca, Spain
14Hospital Universitario Morales Messeguer, Murcia, Spain
15Hematology, Hospital Universitario La Paz-Idipaz, Madrid, ESP
16Laboratory of Hematology, CHU Lille, Lille, France
17Cancer Research Institute, INSERM Unité Mixte de Recherche (UMR)-S 1172, F-59000 Lille, CHU Lille, Laboratory of Hematology, F-59000 Lille, Lille, France
18Department of Oncology, Hematology and Palliative Care, Marienhospital Düsseldorf, Düsseldorf, Germany
19Department for Hematology, Cell Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany
20Service d’Hématologie, Centre Hospitalier Universitaire de Nîmes, Nîmes, France
21Department of Medicine III, Klinikum rechts der Isar, Technical University Munich (TUM), Munich, Germany
22Centre Hospitalier Régional d’Orléans, Orleans, FRA
23Department of Hematology, University Hospital of Salamanca, Salamanca, Spain
24Service d'Hématologie Séniors, Hôpital Saint-Louis, Université Paris 7, Paris, France
25Departamento de Hematología, Hospital Clínico Universitario de Salamanca (CAUSA/IBSAL), Salamanca, Spain
26Hematology Department, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain

5:30 PM

Guillermo Garcia-Manero, MD1, Kimo Bachiashvili, MD2, Harshad Amin, MD3,4*, Elie Traer, MD, PhD5, Daniel A. Pollyea, MD6, David A. Sallman, MD7, Aref Al-Kali, MD8, Larry D. Cripe, MD9, Jesus G Berdeja, MD10, Elizabeth A. Griffiths, MD11, Sanjay R Mohan, MD, MSCI12, Yuri Sano, MD13, Aram Oganesian, PhD14*, Harold N. Keer, MD, PhD13 and Abdulraheem Yacoub, MD15

1The University of Texas MD Anderson Cancer Center, Houston, TX
2University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, AL
3Boca Raton Clinical Research, Boca Raton, FL
4Boca Raton Cancer Research, Boca Raton, FL
5Oregon Health & Science University, Portland
6University of Colorado Cancer Center, Denver, CO
7Moffitt Cancer Center, Tampa, FL
8Mayo Clinic, Rochester, Rochester, MN
9Indiana University Health, Indianapolis, IN
10Sarah Cannon Research Institute, Nashville, TN
11Roswell Park Comprehensive Cancer Center, Buffalo, NY
12Vanderbilt University School of Medicine, Vanderbilt Ingram Cancer Center, Nashville, TN
13Astex Pharmaceuticals Inc., Pleasanton, CA
14Astex Pharmaceuticals, Inc., Pleasanton, CA
15The University of Kansas Clinical Cancer Research Center, Leawood, KS

5:45 PM

Amer M. Zeidan, MD1, Caroline Fradette, PhD2, Anna Rozova, MD2*, Noemi Toiber Temin, MA2* and Fernando Tricta, MD2

1Yale University, New Haven, CT
2Chiesi Canada Corporation, Toronto, ON, Canada

*signifies non-member of ASH